Top Markets
Coin of the day
Aeglea BioTherapeutics, Inc. Aeglea BioTherapeutics, Inc.

Aeglea BioTherapeutics, Inc.

AGLE
Rangering i aksjer #23495
Aeglea BioTherapeutics, Inc. is a clinical-stage biotechnology firm dedicated... Aeglea BioTherapeutics, Inc. is a clinical-stage biotechnology firm dedicated to creating human enzyme therapies for rare metabolic diseases. Their leading candidate, pegzilarginase, a recombinant human Arginase 1, is currently in the pivotal Phase III PEACE trial to assess its safety and effectiveness for treating Arginase 1 deficiency. Furthermore, the company is developing AGLE-177, a polyethylene glycol modified enzyme, which is progressing through Phase I/II clinical trials for homocystinuria. Their early-stage pipeline includes AGLE-325 for cystinuria, along with other ongoing research initiatives. Founded in 2013, the company was initially known as Aeglea BioTherapeutics Holdings, LLC, changing its name to Aeglea BioTherapeutics, Inc. in March 2015. It is based in Austin, Texas.
Aksjekurs
$19.30
Sist synkronisert: 2023-12-26
Markedsverdi
$72.77M
Endring (1 dag)
6.22%
Endring (1 år)
0.00%
Land
US
Handel Aeglea BioTherapeutics, Inc. (AGLE)

Kategori

EPS for Aeglea BioTherapeutics, Inc. (AGLE)
EPS per 2026 TTM: 0
Ifølge de siste økonomiske rapportene og aksjekursen til Aeglea BioTherapeutics, Inc. er selskapets nåværende EPS (TTM) 0. Ved slutten av 2026 hadde selskapet en EPS på 0, lik EPS-en i 2026 som var 0.
EPS-historikk for Aeglea BioTherapeutics, Inc. fra 2026 til 2026
EPS ved slutten av hvert år
År EPS Endre
Ikke nok data for de angitte datoene.
EPS for lignende selskaper eller konkurrenter
Selskap EPS EPS-forskjell Land
$17.32 -
US
$27.74 -
NL
$-7.98 -
US
$-5.29 -
AU
- -
CH